HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Singla H, Munshi A.
Crit Rev Oncog · journal article · DOI 10.1615/critrevoncog.2020037108 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för CP-724714. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
13 hitsInhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.
Rahman A, Henry KM, Herman KD, Thompson AA, Isles HM, Tulotta C, Sammut D, Rougeot JJ, Khoshaein N, Reese AE, Higgins K, Tabor C, Sabroe I, Zuercher WJ, Savage CO, Meijer AH, Whyte MK, Dockrell DH, Renshaw SA, Prince LR.
Elife · research support, non-u.s. gov't; research-article; journal article · DOI 10.7554/elife.50990Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL, Leonard E, Matovina C, Harris M, Herbst G, Kulkarni A, Zhai J, Jiang H, Carey TE, Brenner JC.
Mol Pharmacol · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.118.115162Store operated calcium entry is altered by the inhibition of receptors tyrosine kinase.
Emeriau N, de Clippele M, Gailly P, Tajeddine N.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.24685Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Dong L, Meng F, Wu L, Mitchell AV, Block CJ, Zhang B, Craig DB, Jang H, Chen W, Yang Q, Wu G.
Int J Oncol · research-article; journal article · DOI 10.3892/ijo.2017.4108Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, Qu L, Shou C, Zhao Z.
Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep20502Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.
Woodhead JL, Yang K, Siler SQ, Watkins PB, Brouwer KL, Barton HA, Howell BA.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2014.00240Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF.
Toxicol Sci · journal article · DOI 10.1093/toxsci/kfp033Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.
Gundla R, Kazemi R, Sanam R, Muttineni R, Sarma JA, Dayam R, Neamati N.
J Med Chem · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/jm7013875Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.
Cancer Res · journal article · DOI 10.1158/0008-5472.can-06-3559Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A.
Cancer Chemother Pharmacol · clinical trial, phase ii; multicenter study; journal article · DOI 10.1007/s00280-007-0579-4Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F, Letrent SP, Sharma A.
Cancer Chemother Pharmacol · clinical trial, phase i; journal article · DOI 10.1007/s00280-007-0427-6First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW.
Clin Cancer Res · clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-06-1539